Post-Treatment Molecular Biomarker Reassessment in Advanced Endometrial Cancer: An Evidence-Aware Framework for Precision Therapy

Molecular classification has transformed treatment selection in endometrial cancer (EC), but most biomarkers are defined at diagnosis and may not represent the biological state of tumors after therapeutic exposure. In advanced, recurrent, or metastatic EC, treatment can reshape target expression, hormone dependence, immune context, signaling pathways, and DNA damage response (DDR), raising an important clinical question: which treatment-relevant features should be reassessed after progression, and how should the results inform subsequent therapy? This review synthesizes evidence across immune, endocrine, human epidermal growth factor receptor 2 (HER2) and pathway-directed, DDR-directed, and platinum–taxane treatment contexts. We focus on biomarkers that can be evaluated through repeat tissue biopsy, circulating tumor DNA, functional assays, and clinical treatment history, and distinguish biological plausibility from clinical actionability. The evidence is uneven. HER2 evolution and clinical measures of platinum sensitivity have comparatively direct EC-specific human support, whereas hormone receptor dynamics, estrogen receptor 1 (ESR1) evolution, and selected immune features remain clinically emerging, and pathway-rebound and functional DNA repair readouts are largely investigational. We therefore propose an evidence-aware framework for post-treatment biomarker reassessment that prioritizes whether the biological rationale for a previous therapy remains valid, has been weakened, or has been replaced by an alternative dependency. Prospective longitudinal studies are needed to determine when reassessment improves treatment selection and patient outcomes.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-13
DOI
https://doi.org/10.3390/ijms272210193
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-Treatment Molecular Biomarker Reassessment in Advanced Endometrial Cancer: An Evidence-Aware Framework for Precision Therapy

Xiaofeng Jin, Fan Fei, Meng Ye, Lili Kong et al.
2 links
International Journal of Molecular Sciences
Endometrial and Cervical Cancer Treatments
article

Post-Treatment Molecular Biomarker Reassessment in Advanced Endometrial Cancer: An Evidence-Aware Framework for Precision Therapy

Xiaofeng Jin, Fan Fei, Meng Ye, Lili Kong, Shenyan Yang
article en

Abstract

Molecular classification has transformed treatment selection in endometrial cancer (EC), but most biomarkers are defined at diagnosis and may not represent the biological state of tumors after therapeutic exposure. In advanced, recurrent, or metastatic EC, treatment can reshape target expression, hormone dependence, immune context, signaling pathways, and DNA damage response (DDR), raising an important clinical question: which treatment-relevant features should be reassessed after progression, and how should the results inform subsequent therapy? This review synthesizes evidence across immune, endocrine, human epidermal growth factor receptor 2 (HER2) and pathway-directed, DDR-directed, and platinum–taxane treatment contexts. We focus on biomarkers that can be evaluated through repeat tissue biopsy, circulating tumor DNA, functional assays, and clinical treatment history, and distinguish biological plausibility from clinical actionability. The evidence is uneven. HER2 evolution and clinical measures of platinum sensitivity have comparatively direct EC-specific human support, whereas hormone receptor dynamics, estrogen receptor 1 (ESR1) evolution, and selected immune features remain clinically emerging, and pathway-rebound and functional DNA repair readouts are largely investigational. We therefore propose an evidence-aware framework for post-treatment biomarker reassessment that prioritizes whether the biological rationale for a previous therapy remains valid, has been weakened, or has been replaced by an alternative dependency. Prospective longitudinal studies are needed to determine when reassessment improves treatment selection and patient outcomes.

International Journal of Molecular SciencesVol. 27(22)
Ningbo University (CN), Ningbo First Hospital (CN)
National Natural Science Foundation of China
Good health and well-being
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon